AC Immune (ACIU) Investor presentation summary

Strategic focus and pipeline overview

• Precision prevention approach targets neurodegenerative diseases with active immunotherapies and small molecule programs.

• Pipeline includes candidates for Alzheimer's and Parkinson's diseases, with multiple assets in clinical phases and partnerships with major pharma companies.

• Over CHF 4.3 billion in potential milestones from strategic partnerships; cash reserves of CHF 91.4 million fund operations through Q3 2027.

Key clinical programs and milestones

• ACI-35.030 (anti-pTau) is the only active immunotherapy in a prevention study for pre-symptomatic Alzheimer's disease.

• ACI-24.060 (anti-Abeta) targets hallmark proteins in Alzheimer's and Down syndrome, showing dose-dependent immune response and favorable safety.

• ACI-7104.056 (anti-a-syn) in Phase 2 for early Parkinson's disease demonstrates robust antibody response, target engagement, and stabilization of disease biomarkers.

• NLRP3 inhibitor ACI-19764 shows strong preclinical efficacy in neuroinflammation models and has entered Phase 1 trials.

Clinical results and biomarker insights

• ACI-7104.056 group showed stable neurofilament light chain and dopamine transporter imaging, suggesting slowed neurodegeneration and pathology stabilization in PD.

• ACI-24.060 demonstrated significant Abeta plaque reduction in preclinical models and sustained immune response in clinical cohorts.

• No significant safety concerns observed in interim analyses for both ACI-7104.056 and ACI-24.060; most adverse events were mild and transient.